Sanofi and MyoKardia end heart disease drug collaboration
Bringing an end to a four-year partnership, Sanofi has terminated its agreement with MyoKardia to jointly develop small-molecule therapeutics, targeting genetic mutations associated with certain heart diseases.
Read More
